See more : RAVENO Capital AG (TUF.DE) Income Statement Analysis – Financial Results
Complete financial analysis of 908 Devices Inc. (MASS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 908 Devices Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Hindustan Copper Limited (HINDCOPPER.BO) Income Statement Analysis – Financial Results
- Martin Midstream Partners L.P. (MMLP) Income Statement Analysis – Financial Results
- bioMérieux S.A. (BMXXY) Income Statement Analysis – Financial Results
- GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS) Income Statement Analysis – Financial Results
- Zumtobel Group AG (ZMTBY) Income Statement Analysis – Financial Results
908 Devices Inc. (MASS)
About 908 Devices Inc.
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 50.23M | 46.85M | 42.21M | 26.89M | 17.97M | 22.05M |
| Cost of Revenue | 24.91M | 20.83M | 18.97M | 11.97M | 9.83M | 9.66M |
| Gross Profit | 25.32M | 26.02M | 23.23M | 14.92M | 8.14M | 12.39M |
| Gross Profit Ratio | 50.41% | 55.54% | 55.05% | 55.49% | 45.31% | 56.19% |
| Research & Development | 21.90M | 17.53M | 13.07M | 8.24M | 8.99M | 9.53M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 46.18M | 43.88M | 32.24M | 12.50M | 11.29M | 9.30M |
| Other Expenses | 0.00 | 1.82M | 386.00K | -6.03M | 301.00K | 50.00K |
| Operating Expenses | 68.08M | 61.41M | 45.30M | 20.74M | 20.29M | 18.83M |
| Cost & Expenses | 92.99M | 82.23M | 64.28M | 32.71M | 30.12M | 28.49M |
| Interest Income | 6.48M | 2.03M | 500.00K | 100.00K | 200.00K | 0.00 |
| Interest Expense | 201.00K | 129.00K | 486.00K | 976.00K | 1.53M | 1.15M |
| Depreciation & Amortization | 2.38M | 1.61M | 925.00K | 831.00K | 900.00K | 896.00K |
| EBITDA | -34.03M | -31.82M | -20.94M | -11.01M | -10.94M | -5.49M |
| EBITDA Ratio | -67.74% | -75.52% | -51.37% | -44.04% | -60.89% | -24.91% |
| Operating Income | -42.76M | -35.38M | -22.07M | -5.82M | -12.14M | -6.44M |
| Operating Income Ratio | -85.13% | -75.52% | -52.29% | -21.62% | -67.57% | -29.20% |
| Total Other Income/Expenses | 6.15M | 1.82M | -100.00K | -7.00M | -1.23M | -1.10M |
| Income Before Tax | -36.61M | -33.56M | -22.17M | -12.82M | -13.37M | -7.54M |
| Income Before Tax Ratio | -72.89% | -71.64% | -52.53% | -47.66% | -74.41% | -34.17% |
| Income Tax Expense | -211.00K | -1.82M | -53.00K | -5.88M | 1.83M | 50.00K |
| Net Income | -36.40M | -31.74M | -22.12M | -6.94M | -15.20M | -7.54M |
| Net Income Ratio | -72.47% | -67.75% | -52.40% | -25.79% | -84.60% | -34.17% |
| EPS | -1.13 | -1.01 | -0.79 | -0.25 | -0.58 | -0.40 |
| EPS Diluted | -1.13 | -1.01 | -0.79 | -0.25 | -0.58 | -0.40 |
| Weighted Avg Shares Out | 32.21M | 31.49M | 27.96M | 27.27M | 26.20M | 18.98M |
| Weighted Avg Shares Out (Dil) | 32.24M | 31.49M | 27.96M | 27.27M | 26.20M | 18.98M |
5 ‘Strong Buy' Stocks to Buy Under $10, and Cathie Wood's Ark Owns 2 of Them
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Touchlight Completes Expansion, Creating One of the World’s Largest DNA Manufacturing Facilities in London, UK
HAMPTON, England--(BUSINESS WIRE)--Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion of its UK manufacturing facility, housed in a repurposed Victorian waterworks on the banks of the...
Commsignia and Mitsubishi Electric Agree to Partnership for Delivery of Advanced V2X Solutions for Vehicles
TOKYO--(BUSINESS WIRE)--Commsignia Ltd. and Mitsubishi Electric Corporation announced today that they have agreed to form a strategic partnership to deliver Vehicle-to-Everything (V2X) technology combining Commsignia's V2X solution and Mitsubishi Electric's High-Definition Locator (HDL) technology in a V2X platform that will...
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that the U.S. Food and Drug Administration (FDA) approved XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use in patients 18 years of age...
Veracode voor de tiende keer achtereenvolgend uitgeroepen tot Leader in het Magic Quadrant™ voor het testen van applicatiebeveiliging
BURLINGTON, Mass.--(BUSINESS WIRE)--Veracode, een toonaangevende wereldwijde leverancier van oplossingen voor applicatiebeveiligingstests is voor de tiende keer op rij gepositioneerd als leider in het 2023 Gartner Inc. Magic Quadrant for Application Security Testing. Het bedrijf is achtereenvolgend als leider erkend sinds...
VIA Names Tremell Brown Deputy Chief Executive Officer
SAN ANTONIO--(BUSINESS WIRE)--VIA Metropolitan Transit has named one of its own to its No. 2 leadership position, selecting Tremell Brown, a 33-year veteran of the agency, to serve as Deputy CEO. Brown began his career at VIA in 1990 as...
Watts Water Technologies to Participate in the Stifel 2023 Cross Sector Insight Conference
NORTH ANDOVER, Mass.--(BUSINESS WIRE)--Watts Water Technologies, Inc. (NYSE: WTS) today announced that Robert J. Pagano, Jr., Chief Executive Officer & President; Shashank Patel, Chief Financial Officer; Andre Dhawan, Chief Operating Officer; and Diane McClintock, Senior Vice President FP&A and Investor...
ReNAgade Therapeutics lanceert met meer dan $300 miljoen in een financiering serie A om het grenzeloze potentieel van RNA-geneeskunde te ontsluiten
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ReNAgade Therapeutics, een bedrijf dat het grenzeloze potentieel ontsluit voor RNA-geneesmiddelen om ziektes te corrigeren, kondigde vandaag een financieringsronde van serie A van $300 miljoen aan, geleid door MPM BioImpact en F2 Ventures. Deze bekendmaking is officieel geldend...
E Ink Showcases Latest Color Products, E Ink Spectra™ 6 and E Ink Gallery™ 3 Outdoor, at SID Display Week 2023
BILLERICA, Mass.--(BUSINESS WIRE)--E Ink (8069.TWO), the originator, pioneer, and global commercial leader in ePaper technology, today announced its participation during SID Display Week 2023 at the Los Angeles Convention Center. As the premier event for the global electronic display and...
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.30 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports